Collaboration is focused on optimizing and advancing a small molecule derived from the tetracycline class of compounds.
Families of Spinal Muscular Atrophy (FSMA) and Paratek Pharmaceuticals extended their R&D collaboration to develop a drug candidate for the treatment of spinal muscular atrophy.
The collaboration is focused on optimizing and advancing into the clinic a novel small molecule within Paratek’s library derived from the tetracycline class of compounds.
“We are excited by the progress in our program with Paratek, which in the past year has demonstrated positive results in early cell models of this disease,” remarks Kenneth Hobby, executive director of FSMA.
